Navigation Links
New hope in fight against multi-resistant germs
Date:2/13/2013

This press release is available in German.

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

One highly promising drug candidate is now scheduled for testing in clinical trials. The substance, developed by the British pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers of patient samples that are invaluable in studying the different diseases patients are suffering from - samples that have, until recently, rarely been recruited for research purposes. Now, scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, and at the TWINCORE Centre for Experimental and Clinical Infection Research in Hannover, Germany, aim to study such patient samples for a five-year-period. Part of a special collection at the Hannover Medical School's biobank, the samples will allow researchers to find out more about the etiology, course, and characteristic marker substances of infectious diseases. IMI, the Innovative Medicines Initiative, has awarded the scientists research grants totaling 6 million Euros as part of the COMBACTE (Combating Bacterial Resistance in Europe) project. IMI is a joint initiative by the European Union and the pharmaceutical industry. Dr. Frank Pessler, who heads TWINCORE's "Biomarkers in Infectious Diseases" research group, secured the grant and is the project's coordinator at HZI. Under his helmage, the scientists, along with their colleagues in Paris, Barcelona, and Philadelphia, will be searching for biomarkers - molecules that are unique to a particular disease and which may provide information about if the diagnosis was correct and whether or not the therapy is working.

The new antibiotic, GSK1322322, targets gram-positive bacteria including methicillin-resistant strains of Staphylococcus aureus - notorious MRSA - capable of causing serious skin and wound infections. Gram-positive germs are also frequently the culprit behind pneumonia. The drug targets the bacterial enzyme peptide deformylase. Phase I clinical trials, designed to evaluate a new drug's tolerability and safety profile, have already successfully concluded and showed only minor adverse effects. If the next study shows that GSK1322322 does not bestow any added benefit compared to current treatments, it will not be admitted into the next round of clinical trials. "This is where COMBACTE's added scientific value comes into play. In case this happens, the samples that were obtained will still offer insights into the infections they were supposed to treat, and perhaps aid in developing other better treatments" Frank Pessler explains.

Besides Pessler's own group, research teams headed by Prof. Susanne Hussler, Prof. Singh Chhatwal, Prof. Dietmar Pieper, Dr. Eva Medina, Prof. Irene Wagner-Dbler, Dr. Robert Geffers and Prof. Frank Klawonn are also involved in the project. Each team contributes its own special know-how, and, in concert, they are an excellent force. Adds Pessler: "Where else do you find this many experts from all these different disciplines under one roof, some of them even on the same floor? It makes the whole collaboration smooth and efficient."


'/>"/>

Contact: Jan Grabowski
jan.grabowski@helmholtz-hzi.de
49-531-618-11407
Helmholtz Centre for Infection Research
Source:Eurekalert  

Related medicine news :

1. WeightLossApp.com: The Skinny: Fighting Obesity in the Workplace Through an Innovative Mobile Application
2. Tiger Schulmann's MMA Student, Uriah Hall, Debuts on The Ultimate Fighter
3. Scientists Explore How Zinc Fights Off Infection
4. Electrical Brain Stimulation Plus Drug Fights Depression: Study
5. Tree-Savers™ Reports Successful Launch of Private St Beetle Lab; 100,000 Predator Beetles Now Available to Fight HWA Infestation
6. Scientists identify new strategy to fight deadly infection in cystic fibrosis
7. Bacterial supplement could help young pigs fight disease
8. Bioethics leader calls for bold approach to fighting obesity
9. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
10. Vaccines Might Become Another Way to Fight Cancer
11. New American Chemical Society podcast: Leaves of carob tree fight food-poisoning bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope in fight against multi-resistant germs
(Date:3/28/2017)... ... 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay Area ... about women’s hair loss. Although hair transplant procedures can be seen as more of ... genetics can be two reasons a woman may see her hair thinning. , “We ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... satisfaction in their profession as their value increases in the healthcare workforce, according ... resources such as job boards, career fairs, and candidate leads to healthcare employers ...
(Date:3/27/2017)... ... 2017 , ... New patients who have sleep apnea in Aurora, ... without a referral. Sleep apnea is often left untreated because patients are not familiar ... chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea in ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... transitioned to the OSEHRA popHealth Community in 2014. It is the ... and the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology: